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Background: Benzodiazepine (BZD), the long-term treatment of which is harmful for cognitive function, is widely
prescribed by General Practitioners in Spain. Based on studies performed in other countries we designed a
nurse-led BZD withdrawal program adapted to Spanish Primary Care working conditions.
Results: A pseudo-experimental (before-after) study took place in two Primary Care Centres in Barcelona. From a
sample of 1150 patients, 79 were identified. They were over 44 years old and had been daily users of BZD for a period
exceeding six months. Out of the target group 51 patients agreed to participate. BZD dosage was reduced every 2–4
weeks by 25% of the initial dose with the optional support of Hydroxyzine or Valerian. The rating measurements were:
reduction of BZD prescription, demographic variables, the Short-Form Health Survey (SF-12) to measure quality of life,
the Medical Outcomes Study (MOS) Sleep Scale, and the Goldberg Depression and Anxiety Scale.
By the end of the six-month intervention, 80.4% of the patients had discontinued BZD and 64% maintained abstinence
at one year. An improvement in all parameters of the Goldberg scale (p <0.05) and in the mental component of SF-12
at 3.3 points (p = 0.024), as well as in most components of the MOS scale, was observed in the group that had
discontinued BZD. No significant differences in these scales before and after the intervention were observed in the
group that had not discontinued.
Conclusions: At one year approximately 2/3 of the patients had ceased taking BZD. They showed an overall
improvement in depression and anxiety scales, and in the mental component of the quality of life scale. There was no
apparent reduction in the sleep quality indicators in most of the analysed components. Nurses in a Primary Care setting
can successfully implement a BZD withdrawal program.
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Long-term treatment with Benzodiazepine (BZD) is
harmful at varying cognitive levels [1]. Even though
there is a clear association between the use of BZD by
the elderly and an increased risk of falls, fractures, and
road traffic accidents BZD is still widely prescribed by
General Practitioners in Spain [2-4]. In fact, BZD is
taken by up to 10% of the population in most developed
countries [5].
Time constraints and a general lack of motivation in
dealing with mental health issues on the part of General* Correspondence: Xavier.Mundet@uab.cat
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distribution, and reproduction in any mediumPractitioners have contributed significantly to the ele-
vated and inappropriate use of BZD in Primary Care [6].
Our study attempted to address this issue by giving
nursing professionals (as opposed to General Practi-
tioners) the leading role in managing BZD withdrawal
programmes. Our final objective was to achieve a nurse-
led success rate for the programme equivalent to that
obtained by General Practitioners.
Due to the fact that the number of studies carried out
in Spain focusing on BZD withdrawal is very limited,
our guidelines were based on strategies employed by
General Practitioners in other countries. After reviewing
the literature on BZD withdrawal programs, and using
the study by Curran et al. in the United Kingdom as a
main reference [7], we designed a programme to be
managed by nursing professionals in Spanish Primarytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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who volunteered to participate would cease BZD con-
sumption after six months, and that abstinence would
be maintained for at least a further six months (twelve
months in total), and (b) reduction of BZD was not
harmful for the patient.
Methods
Study design
This is a before-after pseudo experimental study con-
ducted in two large Primary Care Centres based in
Barcelona (Spain). It was approved by the local Institut
Català de la Salut-Barcelona ethics committee.
Participants
Nurses
Five qualified Primary Care nurses with varying levels of
clinical experience agreed to participate. They were
given training with respect to BZD usage and withdrawal
programs in two 2-hour seminars which covered the fol-
lowing main topics: “Normal Sleep Physiology”, “Sleep
Hygiene and Insomnia”, “Benzodiazepine History”, and
“Models and Therapies for Withdrawal Programs”. The
nurses were trained in assessing patients’ needs for
pharmacological support so they could choose, at their
clinical discretion, to give either a prescription of Hydro-
xyzine (25 mg per day) or advice on using over-the-
counter Valerian products which have good tolerance,
low risk, and reduced cost. Finally, they were provided
with a thorough explanation of our protocol.
Patients
We identified patients of both sexes, over 44 years of
age, who had used BZD daily for a period of more than
6 months. Participation was voluntary and written
informed consent was obtained. Exclusion criteria were:
epilepsy, cognitive impairment or dementia, hearing loss,
severe visual defects, palliative care, and severe psychi-
atric illness. In addition, patients whose General Practi-
tioner considered that their BZD withdrawal would be
not be clinically appropriate were excluded.
Protocol and baseline measures
In a similar manner to Curran et al. we assessed several
functions, including quality of life and sleep. We
additionally employed The Goldberg Scale for Depres-
sion and Anxiety to better understand BZD usage.
Patients who met the inclusion criteria were informed
by their doctor about the study and the benefits of ceas-
ing BZD. If they agreed to participate they were asked to
complete a socio-demographic data collection question-
naire. Their responses were then evaluated by nurses
who conducted a semi-structured interview assessing
their attitudes and beliefs about BZD and sleep. Inaddition to gathering administrative data from the ques-
tionnaire, the nurses described the risks and benefits of
long term BZD consumption, side effects, and possible
dependence. They also briefly explained the programme
and the implications of participating in the study. Three
self-administered questionnaires were given to patients
to be completed at home: The Short-Form Health Sur-
vey (SF-12) to measure quality of life [8,9], the Medical
Outcomes Study (MOS) sleep scale [10], and the
Goldberg Depression and Anxiety scale [11]. Finally, a
date was fixed to commence the withdrawal program.
The general outline of the intervention program and
each visit is summarized in Table 1.
Patients were evaluated by nurses every four weeks for
the first 12 weeks. An assessment with the Goldberg
Depression and Anxiety Scale, the quality of life scale
(SF-12), and MOS sleep scale was performed at the ini-
tial visit, and at 12 and 24 weeks.
With regard to medication cessation, the baseline was
the same in all cases. Patients could choose to continue
taking either the same BZD or the equivalent dose of
Diazepam which was then reduced by 25% every 2–4
weeks. If, according to the nurse’s assessment, pharma-
cological support with Hydroxyzine (25 mg per day) or
Valerian was needed, the doctor would then be con-
sulted. The doctor’s supervisory role was to review the
nurse’s clinical decision, check the medication plan, and
issue a prescription, if appropriate. The nurses also had
the opportunity to provide feedback to the doctor. Infor-
mation was extracted from patients’ notes, surveys, and
questionnaires. The primary endpoint (no consumption
of BZD after six and twelve months) variable was
obtained verbally from the patient and confirmed by
prescription data.
Study outcome measures
The following variables were collected: socio demo-
graphic, toxic habits, antidepressant consumption, co-
morbidity, use of BZD, and data from the assessment
scales: the Goldberg Depression and Anxiety Scale, The
Short-Form Health Survey (SF-12), and The Medical
Outcomes Study (MOS) sleep scale.
Statistical analysis
A data paired sample was calculated. Taking as a refer-
ence the results from various studies, a minimum BZD
cessation of 20% was considered clinically relevant.
Therefore, 40 patients (alpha error of 0.05 and beta error
of 0.2) were required to give a statistically significant re-
sult. Mean with SDs and proportions were calculated for
all variables. The Chi-square test was used to compare
categorical data, and an unpaired Student t test was used
to compare continuous variables. A two-tailed value of
P<0.05 was considered statistically significant. Cohen’s d
Table 1 Intervention and data collection
Visit Selection Selection of candidates for study
Patient: Completes questionnaire.
Doctor: Checks that patient meets criteria for study (reviews results of data collection questionnaire + nurse interview).
Nurse: Semi-structured interview with patient. Consent obtained from patient.
If patient accepts: Questionnaires / test (T) given to patient + set up of start date (VISIT 0)
Visit 0 Collect questionnaires / tests + Brief educational intervention (BEI) + detoxification regimen given to patient
Visit 4 BEI + detoxification regimen plan given
Visit 8 BEI + detoxification regimen + Questionnaires / test (T) given to patient
Visit 12 BEI + Collect questionnaires / tests and new Questionnaires / test (T) given to patient
Visit 24 BEI + Collect questionnaires / tests (T)
BEI: Brief educational Intervention.
T: test. Include: SFHF 12, Goldberg, and MOS.
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ferent variables.
Results
1150 patients were attended by their Primary Care doctors
over an inclusion period of 3 months. From the 79 patients
who met the inclusion criteria, 51 agreed to participate in
the study (36 females and 15 males) (Figure 1). The mean
age was 70.4 years (95% CI: 66.4 to 73.9 years). Socio-
demographic characteristics are presented in Table 2.2




51 patients agreed 
to participate
79 met 





Figure 1 Flow chart describing the progression of participants duringRegarding long term consumption, 22 patients (43.1%)
had been taking BZD for over 6 years, 21 patients
(41.2%) between 1 and 6 years, and 8 patients (15.7%)
for less than 1 year.
25 patients (50%) began treatment with BZD due to
insomnia, with an average consumption period of 5.12
years; 9 patients (18%) were taking BZD due to anxiety,
with an average consumption period of 10.67 years, and
5 patients (10%) were depressed, with an average con-
sumption period of 4.15 years. 11 patients (22%) were8 patients did 
not agree to 
participate
3 patients reduced dose 
of BZD
s did not 
eed.
7  patients excluded 
during the program
the study.
Table 2 Patients’ features
Features N - (%)
Natives or residents for more than 5 years 49 (96.1)
Education:
Primary school 14 (27.5)
Secondary school 34 (66.7)




Active workers 9 (17.6)
Consumption of drugs:
Did not use antidepressants 42 (82)
Consumed antidepressants: 9 (18)
a) SSRI 7 (14)
b) MAO 1 (2)
c)Tricycle Antidepressants 1 (2)
Chronic disease:






Other drugs 1 ( 2)
Cause of BZD consumption
Sleep disorder 25 (0.5)
Anxiety 9 (0.2)
Depression 5 (0.1)
Other diagnoses 11 (0.2)
SSRI: Selective Serotonin Reuptake Inhibitor.
MAOI: Monoamine oxidase Inhibitors.
COPD: Chronic Obstructive Pulmonary Disease.
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vorce, and somatization.
46 patients remembered why BZD had been originally
prescribed, with an average consumption period of 7.11
years. In contrast, 5 patients could not recall the reason
for their original prescription, with an average consump-
tion period of 4 years.
Among the patients who agreed to participate in the
study 40 (78.4%) were taking short-acting BZD, 8
(15.7%) were using long acting BZD, and 3 (5.9%) took
other non-barbiturate hypnotics known as Z-drugs. The
BZD most consumed in our study was 1 mg of Loraze-
pam (58%), equivalent to 10.4 of Diazepam (Figure 2).
The amount of information conveyed by the physician
to the patient, when the prescription was first issued,
was nil in the case of 31 patients, minimal for 13
patients, and only partial for the remaining 7 patients.By the end of the intervention program, 80.4% of the
patients had stopped their BZD intake and 64.7% main-
tained abstinence for one year.
In the analysis of the Short-Form Health Survey
(SF-12) at baseline the mental component (45.96) con-
sistently achieved a higher score than the physical one
(39.60). Both results showed scores below the population
mean (50).
Within the group of patients who ceased BZD, com-
parative analysis of the SF-12 before the intervention
and at 24 weeks showed an improvement of 3.3 points
(p = 0.02) in the mental component (Table 3). The same
comparative analysis of its physical component was
made, but no statistically significant differences were
observed. Within the group of non-compliance there
were no statistically significant improvements in any of
the physical or mental components.
From analysis of the scales (Table 3) it can be seen that
in the MOS sleep scale, those patients taking BZD
chronically obtained, at the beginning, a higher score in
all parameters of sleep analysis than the population
mean. The average hours of sleep was 6.10 (SD 1.46),
and 16 patients slept an adequate number of hours
(7–8 hours). Within the compliant group results from
the same scale showed no difference in most of the com-
ponents throughout the intervention. Two exceptions
were deterioration in snoring perception and an increase
in breathing difficulty. Within the non-compliance group
there were no statistically significant differences.
Analysis of the Goldberg Depression and Anxiety Scale
at the beginning of the program showed an average
score compatible with depression but not anxiety (break-
points are ≥ 4 for the anxiety scale and ≥ 2 for depres-
sion). The unsuccessful group showed a lower mean in
the depression component at baseline, but without sta-
tistically significant differences between the beginning
and the end of the study. The same group also showed a
higher mean in the anxiety score although still below the
anxiety threshold.
Discussion
The study was designed to show that a BZD withdrawal
program, with nursing professionals as the key element,
can be applicable within the Spanish Primary Care set-
ting. The following points were considered in developing
our program: a) In agreement with many authors,
patients should not be forced to cease their treatment
[12]; b) The use of complementary medicines as co-
adjuvant therapy. Numerous trials have been carried out
using complementary medicines to control withdrawal
symptoms while the patients are on BZD [13-15]. These
trials have highlighted the successful use of Hydroxyzine
[16] due to its good tolerance, low risk, and reduced
cost; c) Tapered dose. Other studies have also focused





flurazepam 30 mg, n=1
zopiclone 7,5 mg, n=1
zolpiden 10 mg, n=2
diazepam 5 mg, n=4 
dipotassiumchlorazepate
alprazolam 0,5 mg, n=2
lormetazepam 0,5 mg, n=2
lormetazepam 1mg, n=2
tetrazepam 50 mg, n=1 
Figure 2 Types of BZD consumed by patients.
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a cost-effective alternative for BZD withdrawal; d)
Pharmacological support. Although cognitive behav-
ioural therapy is an effective adjuvant therapy in BZD
withdrawal programs [19,20] its implementation in daily
practice can have significant cost and time implications.
Several clinical trials have, therefore, focused instead on
providing psychological support to patients during their
withdrawal period, based on identifying the reason pre-
scriptions were initiated and maintained, and patients’
information on dependence and withdrawal symptoms
[21,22]; and e) The use of Valerian for improving sleep.
Whilst Valerian has a subjective improvement on sleep
quality it does not reflect an improvement in sleep onset
latency [23].
After the level of commitment required to successfully
complete the first stage of this programme (i.e. to attend
at least six appointments with the nurse and to complete
multiple assessment questionnaires) had been explained,
28 of the selected patients did not wish to participate.
Most of these patients gave as their reason for refusal the
fact of being in active employment and, therefore, limited
in terms of time. It should also be noted that the study
excluded young patients, which additionally reduced our
patient sample. As a result, our sample group consisted
predominantly of elderly and retired patients (particularly
female pensioners with a low socio-economic level) with
concomitant chronic diseases.
Their socio-demographic features matched those of
patients defined as being at risk of chronic BZD use
[24,25].
Our sample size was large enough to show the benefi-
cial effect of a BZD cessation programme and highlight
the difference between the patients’ condition before
and after the intervention programme. We recognize,
however, that size was the main limitation of the study,and we were unable to obtain statistically significant
differences between patients who successfully completed
the cessation programme and those who did not. The
latter comparison was not, however, a key objective al-
though we consider it could become a useful starting
point for further studies.
It should be pointed out that almost 20% of the
patients consumed antidepressants, mostly from the
Selective Serotonin Reuptake Inhibitor (SSRI) group.
This highlights non-compliance with national guidelines
based on previous studies [26] which advise limiting the
use of BZD to the onset of SSRI treatment. More than
twenty years ago it was reported that the benefit of BZD
was significantly reduced after fifteen days of use [27].
Yet, as our results confirm, BZD continues to be pre-
scribed without due consideration for this benefit/time
restriction.
A comparison revealed that the average daily dose of
BZD in the United Kingdom (equivalent to 5 mg of
Diazepam) [7] was lower than that in our study in Spain
(equivalent to 10 mg of Diazepam). Nevertheless, the
percentage of cessation at six months was the same
in both countries. Results achieved in withdrawal
programmes in both countries were not, therefore, influ-
enced by the initial BZD dosage. In our study, patients
taking a higher initial dose of BZD presented more
sleeping problems in the baseline test than those taking
lower doses; once, however, they had all completed the
program, those who had initially consumed more BZD
did not score higher on the sleeping problem scale. This
finding helped to confirm that the consumption of a
higher dose of BZD does not improve sleep quality
[7,28]. It is noteworthy, that 10% of the patients who
were taking BZD (with its concomitant side effects)
[2,29] in excess of four years were unaware of the reason
for its indication.
Table 3 Comparison of quality of life (SF-12), Goldberg, and MOS scales
No success (12 pacs) Success (39 pacs)
Scale Mean Desv. Est. p Mean Desv. Est. p Effect size Cohen’s
SF·12: physical component
0 41.89 11.62 39.60 8.82 0.25
12 months 49.09 1.63 0.36 39.89 8.36 0.79 1.27
24 months 49.71 2.98 0.58 38.99 7.49 0.52 1.62
SF12: mental component
0 42.79 16.12 45.96 9.88 −0.28
12 months 48.03 11.17 0.28 48.79 9.74 0.08 −0.08
24 months 40.72 19.63 0.43 49.27 9.73 0.02 −0.69
Goldberg anxiety
0 3.75 3.19 3.23 2.65 0.19
12 months 0.75 1,50 0,30 2,33 2,31 0,01 −0.75
24 months 2,67 2,52 1,00 2,26 2,42 0,01 0.17
Goldberg depression
0 2,17 1,85 2,36 2,31 −0.09
12 months 1,00 1,41 0,42 1,62 2,42 0,00 −0.28
24 months 1.00 1,73 0,42 1,55 1,84 0,00 −0.31
Short of Breath Scale
0 75,00 28,44 82,56 24,36 −0.30
12 months 95,00 10,00 0,42 85,64 20,49 0,32 0.51
24 months 100,00 0,00 0,07 90,26 16,46 0,02 0.69
Sleep Adequacy
0 40,00 24,12 56,15 27,30 −0.62
12 months 30,00 34,64 0,07 56,41 22,18 0,96 −1.06
24 months 53,33 11,55 0,06 58,46 26,31 0,36 −0.22
Sleep Disturbance Scale
0 51,88 14,19 55,71 14,78 −0.27
12 months 68,44 10,87 0,19 56,60 13,02 0,73 0.96
24 months 57,92 6,88 0,68 57,31 12,15 0,44 0.06
Sleep Problems Index I
0 61,39 14,32 62,99 9,88 −0.15
12 months 75,00 15,99 0,46 63,85 6,86 0,60 1.17
24 months 67,78 6,94 0,15 65,47 6,69 0,07 0.35
Sleep Problems Index II
0 59,35 11,42 60,94 9,34 −0.16
12 months 71,53 12,86 0,40 61,45 5,54 0,83 1.32
24 months 62,04 6,99 0,47 62,68 6,61 0,18 −0.10
Snoring Scale
0 71,67 35,63 66,15 37,32 0.15
12 months 100,00 0,00 0,18 70,77 35,79 0,24 0.95
24 months 100,00 0,00 0,18 74,87 29,99 0,03 0.97
Somnolence Scale
0 59,44 17,16 73,50 17,54 −0.82
12 months 70,00 20,73 0,21 72,82 15,09 0,86 −0.17
24 months 64,44 20,37 0,12 76,92 14,25 0,25 −0.80
MOS: Medical Outcomes Study.
SF-12: Short-Form Health Survey.
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intervention and at 24 weeks, we saw an improvement
in the mental component but not in the physical one
among the cessation group. These results are similar to
those expected as consumption of BZD should not influ-
ence physical fitness.
In the analysis of the Goldberg scale, the cessation
group showed a statistically significant gradual decrease
in both the anxiety and depression components. These
results are positive when compared with the study by
Curran et al. [7] which, whilst using a different paramet-
ric scale (the Geriatric Depression Scale), reported
neither an improvement nor a deterioration of these
symptoms for the cessation group.
The results of the sleep scale could be interpreted as
being due to a heightened awareness of other underlying
chronic diseases. In fact, a quarter of the patients had
Chronic Obstructive Pulmonary Disease (COPD) and
they should not have been taking BZD as a chronic
treatment. Discontinuing BZD prevents severe symp-
toms being masked, and thus permits early action on po-
tential complications. A 64.7% success rate (percentage
of BZD cessation cases maintained for one year) shows
that, after specific training, nurses in a Primary Care
setting can implement a program with the objective of
achieving the cessation of BZD intake in volunteer
patients, with similar results to studies conducted by
other professionals such as physicians or psychologists
[7,30,31]. Nevertheless, it must be conceded that our
outcome could be partly attributed to an inaccurate
diagnosis of insomnia, mistaking this, and the patient’s
addiction due to tolerance [32], for physiological sleep
disturbances related to age, which are easy to treat
through advice and sleep hygiene. Our results may pro-
vide another overview [33] of the initial and medium
term results of this withdrawal program and represent a
starting point for further studies on effectiveness.Conclusions
Our withdrawal program, conducted by nurses, was suc-
cessful in that a period of one year. 2/3 of the patients in
our sample ceased taking BZD. These results are similar
to studies conducted by other professionals such as phy-
sicians or psychologists. Our work confirms the fact that
nurses in a Primary Care setting can successfully imple-
ment a BZD withdrawal program.Abbreviations
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